Bumetanide — $0 on Listed Strengths

Other medications in Heart & Cardiovascular

• Candesartan
• Cangrelor
• Captopril
• Carvedilol
• Chlorthalidone
• Cholestyramine
• Colesevelam
• Colestipol

What Bumetanide is approved for (FDA label)

Bumetanide tablets, USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets, USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.

Source: Read the full FDA label on DailyMed. Label effective date: September 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Bumetanide (FDA label)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required, and dose and dosage schedule have to be adjusted to the individual patient’s needs (see DOSAGE AND ADMINISTRATION ) .

Source: FDA prescribing information (DailyMed). Set ID: 0fb78afc-d8bc-4ae8-8c0a-6d9c6f7a22c5. SPL document ID: 5b1199a4-6d85-a917-e063-6394a90a1209. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Bumetanide (FDA label)

The most frequent clinical adverse reactions considered probably or possibly related to bumetanide are muscle cramps (seen in 1.1% of treated patients), dizziness (1.1%), hypotension (0.8%), headache (0.6%), nausea (0.6%) and encephalopathy (in patients with pre-existing liver disease) (0.6%). One or more of these adverse reactions have been reported in approximately 4.1% of patients treated with bumetanide. Serious skin reactions (i.e., Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported in association with bumetanide use. Less frequent clinical adverse reactions to bumetanide are impaired hearing (0.5%), pruritus (0.4%), electrocardiogram changes (0.4%), weakness (0.2%), hives (0.2%), abdominal pain (0.2%), arthritic pain (0.2%), musculoskeletal pain (0.2%), rash (0.2%) and vomiting (0.2%).

Source: FDA prescribing information (DailyMed). Set ID: 0fb78afc-d8bc-4ae8-8c0a-6d9c6f7a22c5. SPL document ID: 5b1199a4-6d85-a917-e063-6394a90a1209. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Bumetanide (FDA label)

Bumetanide is contraindicated in anuria. Although bumetanide can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide. Bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected. Bumetanide is contraindicated in patients hypersensitive to this drug.

Source: FDA prescribing information (DailyMed). Set ID: 0fb78afc-d8bc-4ae8-8c0a-6d9c6f7a22c5. SPL document ID: 5b1199a4-6d85-a917-e063-6394a90a1209. Label effective date: September 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.